Cargando…
Humoral immune response to an mRNA-1273 booster after chAdOx1-nCoV-19-priming among patients undergoing hemodialysis
OBJECTIVES: Patients who are undergoing dialysis due to end-stage kidney disease are susceptible to greater coronavirus disease 2019 (COVID-19) complications. While vaccination is seen as the most effective tactic against COVID-19, the dialysis population usually has impaired immune responses to vac...
Autores principales: | Cheng, Bo-Yu, Lin, Ting-Yun, Hung, Szu-Chun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683517/ https://www.ncbi.nlm.nih.gov/pubmed/38035061 http://dx.doi.org/10.4103/tcmj.tcmj_107_23 |
Ejemplares similares
-
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
por: Normark, Johan, et al.
Publicado: (2021) -
Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
por: Sheng, Wang-Huei, et al.
Publicado: (2022) -
Association of Reactogenicity with Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in Patients Undergoing Hemodialysis
por: Lin, Ting-Yun, et al.
Publicado: (2022) -
Comparison of Humoral Antibody Responses and Seroconversion Rates between Two Homologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination in Patients Undergoing Maintenance Hemodialysis
por: Hsiao, Shih-Hsin, et al.
Publicado: (2023) -
Comment on “Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination”
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)